ESMO 2022 | Advances in targeted therapy for head & neck and thyroid cancers

Neil Gross, MD, FACS, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of neoadjuvant therapies for patients with head and neck cancer and the potential of surgical treatment for patients with thyroid cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.